A Benefit-Risk Assessment of Extended-Release Oxybutynin

被引：0
作者：
Martin C. Michel
机构：
[1] University of Essen,Department of Medicine
来源：
Drug Safety | 2002年 / 25卷
关键词：
Oxybutynin; Extended Release; Tolterodine; Immediate Release; Incontinence Episode;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Oxybutynin is a muscarinic receptor antagonist, which has been available for a number of years in its original immediate-release (IR) formulation. While oxybutynin IR has proven effective for the treatment of overactive bladder, its extended use can be limited by adverse effects, particularly dry mouth.
引用
收藏
页码：867 / 876
页数：9
相关论文
共 95 条
[21]  
Sathyan G(1998)Pharmacological characterization of muscarinic receptors in rabbit isolated iris sphincter muscle and urinary bladder smooth muscle Br J Pharmacol 124 883-8
[22]  
Chancellor MB(2002)M3 muscarinic receptors mediate contraction of human urinary bladder Br J Pharmacol 136 641-4
[23]  
Gupta SK(1995)Muscarinic receptor subtypes in the submandibular gland and the urinary bladder of the rabbit: J Auton Pharmacol 15 451-63
[24]  
Comer AM(1996) and Pharmacol Rev 48 531-65
[25]  
Goa KL(2001) functional comparisons of receptor antagonists Br J Pharmacol 132 835-42
[26]  
Douchamps J(1997)Muscarinic receptor subtypes and smooth muscle function J Urol 157 1093-7
[27]  
Derenne F(1995)Pharmacological characterization of muscarinic receptors in dog isolated ciliary and urinary bladder smooth muscle Eur Urol 28 340-4
[28]  
Stockis A(2001)Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland J Urol 166 2232-6
[29]  
Hughes KM(1991)Intravesical application of oxybutynin: mode of action controlling detrusor hypereflexia: preliminary results Pharm Res 8 S-320
[30]  
Lang JC(1988)Intravesical oxybutynin: mode of action assessed by passive diffusion and electromotive administration with pharmacokinetics of oxybutynin and N-desethyl-oxybutynin J Urol 140 47-50
12345678910